Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release

Xencor (NASDAQ:XNCR) maintains a "Strong Buy" rating despite a 60% stock decline, with analysts emphasizing upcoming clinical catalysts for its bispecific antibody pipeline. The company expects to present preliminary Phase 1 data for XmAb819, targeting relapsed/refractory clear cell renal cell carcinoma, in Q4 2025, following initial observations of anti-tumor activity and favorable duration of response. Concurrently, Xencor plans to initiate a Phase 2b trial for its anti-TL1A antibody XmAb942 in ulcerative colitis in H2 2025, supported by positive interim Phase 1b/2a data. Financially, Xencor reported $663.8 million in cash as of June 30, 2025, providing a runway into 2028 against a quarterly burn of approximately $76.8 million.

Analysis

Despite a 60% decline in its stock price, Xencor's (NASDAQ:XNCR) fundamental outlook is viewed positively, primarily driven by its bispecific antibody pipeline and strong financial position. The company's cash reserves of $663.8 million as of June 30, 2025, are projected to fund operations into 2028, mitigating near-term financing risks against a quarterly cash burn of approximately $76.8 million. The key value drivers are two clinical-stage assets with significant upcoming catalysts. First, XmAb819, a bispecific antibody for relapsed/refractory clear cell renal cell carcinoma (ccRCC), is expected to have preliminary Phase 1 data presented in Q4 2025. Early findings from this study are encouraging, showing anti-tumor activity and long duration of response even before a maximum tolerated dose was reached. Second, XmAb942, a monospecific anti-TL1A antibody for Ulcerative Colitis (UC), is set to begin a Phase 2b trial in the second half of 2025, supported by positive interim safety data. This candidate's extended half-life, enabled by the Xtend Fc domain, could provide a competitive advantage in a crowded field that includes therapies from Merck and Roche.

Key Decisions for Investors

• Investors with a higher risk tolerance may view the 60% stock price depreciation as a potential entry point ahead of the primary near-term catalyst, which is the Q4 2025 preliminary data release for XmAb819 in ccRCC.
• The company's strong cash position, providing a runway into 2028, allows for a longer-term investment thesis focused on clinical execution without immediate concern for dilutive financing.
• Portfolio managers should monitor the high binary risk associated with the upcoming XmAb819 data and track the competitive landscape for XmAb942, as its success hinges on demonstrating a clear clinical advantage over established competitors like Merck and Roche.